T-cell avidity and tuning: the flexible connection between tolerance and autoimmunity.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 3462655)

Published in Int Rev Immunol on July 04, 2006

Authors

Jasper G van den Boorn1, I Caroline Le Poole, Rosalie M Luiten

Author Affiliations

1: Netherlands Institute for Pigment Disorders and Department of Dermatology, AMC, University of Amsterdam, Amsterdam, The Netherlands. j.g.vandenboorn@amc.uva.nl

Articles cited by this

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27

Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04

The danger model: a renewed sense of self. Science (2002) 13.85

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95

FOXP3: of mice and men. Annu Rev Immunol (2006) 6.89

Evidence for a differential avidity model of T cell selection in the thymus. Cell (1994) 5.24

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol (2001) 5.17

Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 5.11

A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today (1998) 5.07

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol (2003) 5.01

The cellular mechanism of Aire control of T cell tolerance. Immunity (2005) 4.74

An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet (2003) 4.61

The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47

The immunological synapse. Annu Rev Immunol (2001) 4.45

Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol (2001) 3.95

A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity (1999) 3.88

Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol (2003) 3.88

The many important facets of T-cell repertoire diversity. Nat Rev Immunol (2004) 3.83

Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68

T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol (2001) 3.59

The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol (2000) 3.58

Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol (2001) 3.56

Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol (2005) 3.41

Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity (2001) 3.29

Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity (1995) 3.18

T cell affinity maturation by selective expansion during infection. J Exp Med (1999) 3.08

Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat Immunol (2001) 3.08

Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 2.89

Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc Natl Acad Sci U S A (1997) 2.89

Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science (1994) 2.86

Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol (2001) 2.76

Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J Immunol (1996) 2.70

T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol (2001) 2.51

CD8+ T cell cross-priming via transfer of proteasome substrates. Science (2004) 2.51

Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature (1996) 2.50

Structural basis of T cell recognition. Annu Rev Immunol (1999) 2.45

Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity (2001) 2.44

Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature (2000) 2.39

Selection of the T cell repertoire. Annu Rev Immunol (1999) 2.21

An unusual lineage of alpha/beta T cells that contains autoreactive cells. J Exp Med (1991) 2.16

High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J Exp Med (2000) 2.10

Fine tuning of TCR signaling by CD5. J Immunol (2001) 2.02

Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol (2005) 1.98

Molecular mimicry and autoimmunity. N Engl J Med (1999) 1.95

Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol (2005) 1.88

Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med (2005) 1.85

Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J (2003) 1.84

Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses. Proc Natl Acad Sci U S A (1992) 1.83

Antigen bias in T cell cross-priming. Science (2004) 1.82

Specific T cell recognition of minimally homologous peptides: evidence for multiple endogenous ligands. Immunity (1995) 1.80

Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol (2001) 1.79

Specificity and degeneracy of T cells. Mol Immunol (2004) 1.71

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70

Negative selection during the peripheral immune response to antigen. J Exp Med (2001) 1.59

T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol (2002) 1.56

The level of CD8 expression can determine the outcome of thymic selection. Cell (1992) 1.53

Mature T cell reactivity altered by peptide agonist that induces positive selection. J Exp Med (1996) 1.50

Bm-CPI-2, a cystatin homolog secreted by the filarial parasite Brugia malayi, inhibits class II MHC-restricted antigen processing. Curr Biol (2001) 1.43

CD4+ CD25+ regulatory T cells inhibit the maturation but not the initiation of an autoantibody response. J Immunol (2005) 1.42

Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. J Exp Med (1999) 1.42

Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest (2005) 1.42

The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J Exp Med (2003) 1.38

A T cell clone's avidity is a function of its activation state. J Immunol (2001) 1.35

T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo. J Exp Med (2000) 1.30

Molecular mimicry as a mechanism for virus-induced autoimmunity. Immunol Res (1989) 1.29

High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol (2003) 1.27

Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol (2003) 1.27

CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Proc Natl Acad Sci U S A (2005) 1.27

Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J Immunol (2002) 1.26

Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation. J Immunol (2001) 1.21

Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol (2005) 1.20

Selection and fine-tuning of the autoimmune T-cell repertoire. Nat Rev Immunol (2002) 1.10

Role of CD4 in thymocyte selection and maturation. J Exp Med (1989) 1.08

New views of the immunological synapse: variations in assembly and function. Curr Opin Immunol (2004) 1.08

CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol (1998) 1.04

Dual T cell receptor beta chain expression on human T lymphocytes. J Exp Med (1995) 1.03

Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today (1998) 1.01

Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. J Exp Med (2002) 0.98

Association of HLA-DR4 with vitiligo. J Am Acad Dermatol (1983) 0.97

TCR avidity: it's not how strong you make it, it's how you make it strong. Nat Immunol (2001) 0.95

Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. Eur J Immunol (1998) 0.93

Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo. Br J Dermatol (1999) 0.93

CD8 T cell sensory adaptation dependent on TCR avidity for self-antigens. J Immunol (2005) 0.88

Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. J Immunol (1996) 0.87

Antigen-presenting cell activation: a link between infection and autoimmunity? J Autoimmun (2001) 0.82

Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur J Immunol (2005) 0.81

Development and function of autospecific dual TCR+ T lymphocytes. Int Immunol (1999) 0.79

Thymic expression of a gastritogenic epitope results in positive selection of self-reactive pathogenic T cells. J Immunol (2004) 0.77

Articles by these authors

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66

Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 1.59

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res (2011) 1.50

A central role for inducible heat-shock protein 70 in autoimmune vitiligo. Exp Dermatol (2013) 1.50

Autoimmune etiology of generalized vitiligo. Curr Dir Autoimmun (2008) 1.31

Notch signaling regulates mouse and human Th17 differentiation. J Immunol (2011) 1.21

Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev (2006) 1.12

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12

HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol (2008) 1.11

Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res (2010) 1.09

First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res (2010) 0.96

Cervical cancer vaccines: recent advances in HPV research. Viral Immunol (2003) 0.95

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol (2012) 0.94

Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res (2011) 0.92

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol (2012) 0.89

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci (2003) 0.88

Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res (2004) 0.87

Heme oxygenase-1 expression protects melanocytes from stress-induced cell death: implications for vitiligo. Exp Dermatol (2011) 0.85

Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res (2011) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol (2013) 0.82

Renal angiomyolipoma, fat-poor variant--a clinicopathologic mimicker of malignancy. Virchows Arch (2013) 0.82

De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation. Cancer Res (2009) 0.82

Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res (2011) 0.81

Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region. Pigment Cell Res (2004) 0.79

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol (2012) 0.79

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. Pigment Cell Melanoma Res (2014) 0.79

Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP. In Vitro Cell Dev Biol Anim (2008) 0.79

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res (2014) 0.78

The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res (2014) 0.77

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75

Skin immune system. Cancer Treat Res (2009) 0.75

Vitiligo treatment demystified: a flowchart for stratified treatment approaches. Exp Dermatol (2014) 0.75